Abliva AB Interim Report January – September 2020
KL1333 is on its way to pivotal clinical study - Pivotal study planned for the second half of 2021
Press releases
Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced it has received ...
Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces dosing in the f ...
Abliva doses the first patient in its KL1333 Phase Ia/b clinical study
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the first primary mitochondrial disease patient in the company’s ongoing KL1333 Phase Ia/b study has been dosed. In this third part of the study ...
Abliva’s Mitochondria Day – today at 2 p.m. – 4 p.m. CEST
Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, today on 16 September at 2 p.m. – 4 p.m. CEST. The purpose o ...
Abliva intends to start a pivotal KL1333 study second half 2021
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the company’s Board of Directors has decided to accelerate the KL1333 clinical program, with the intention to start a pivotal Phase II/III clini ...
Abliva arranges Mitochondria Day on 16 September 2020 – preliminary program
Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, on 16 September at 2 p.m. – 4 p.m. CEST. The purpose of the ...
Abliva AB Interim Report January – June 2020
NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner
Abliva arranges Mitochondria Day on 16 September 2020
Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, on 16 September at 2 p.m. – 4 p.m. CEST. The purpose of the ...
Abliva receives positive FDA feedback on its KL1333 development plan
Abliva AB (Nasdaq Stockholm: ABLI) today announced that it has received positive feedback from the US Food and Drug Administration (“FDA”) on its KL1333 clinical development plan for the treatment of ...
Abliva invites you to a virtual Capital Markets Day on June 23
Abliva AB (Nasdaq Stockholm: ABLI), invites you to a virtual Capital Markets Day on 23 June at 3.00 p.m. - 4.30 p.m. The theme of the day will be the company's new strategic focus on primary mitochond ...
Abliva arranges virtual Capital Markets Day on 23 June
Abliva AB (Nasdaq Stockholm: ABLI), invites to a virtual capital markets day on 23 June at 3.00 - 4.30 p.m. CEST. The theme of the day will be the company's new strategic focus on primary mitochondria ...